The primary investment objective of the Scheme is to generate consistent returns by investing in equity / equity related or fixed income securities of Pharma and other associated companies
Expert-managed portfolios tailored to your financial goals and risk appetite.
| Sector Funds | 1M | 3M | 6M | 9M | 1Y | 2Y | 3Y | 4Y | 5Y | 10Y | ALL |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Fund returns | -7.15% | -5.32% | 5.24% | 6.88% | 3.38% | 0.77% | 14.88% | 17.07% | 11.64% | 13.79% | 19.42% |
| Category returns | -7.54% | -3.42% | 10.54% | 13.4% | 8.01% | 3.9% | 18.22% | 18.48% | 12.78% | 13.01% | N/A |
| Absolute returns | -7.15% | -5.32% | 5.24% | 6.88% | 3.38% | 1.54% | 51.66% | 87.91% | 73.48% | 263.95% | 5211.3% |
| Rank within category | 5/19 | 16/18 | 17/18 | 16/18 | 13/17 | 11/14 | 12/12 | 7/10 | 7/9 | 1/4 | N/A |
| Sector Funds | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Yearly returns | -10.58% | 7.61% | 3.64% | 1.68% | 66.44% | 23.93% | -9.9% | 39.15% | 34.04% | -3.34% | 4.25% |
| Q1 returns | -12.47% | 0.87% | -7.37% | 1.47% | -5.7% | -1.15% | -7.5% | -4.25% | 9.06% | -8.69% | -3.88% |
| Q2 returns | 2.17% | -4.95% | 6.95% | -6.5% | 31.59% | 22.06% | -10.12% | 17.1% | 4.01% | 7.82% | 13.83% |
| Q3 returns | 7.77% | 0.19% | 10.7% | -1.11% | 19.5% | 0.73% | 8.2% | 11.23% | 17.22% | -4.42% | 0.44% |
| Q4 returns | -7.22% | 12.03% | -5.5% | 8.38% | 12.24% | 1.97% | 0.15% | 11.58% | 0.8% | 2.72% | -5.13% |
1% on or before 1M, Nil after 1M
| Alpha | -0.170307 |
| Beta | 0.8806 |
| Sharpe Ratio | 0.241448 |
| Sortino Ratio | 0.506218 |
| R-Squared | 0.9329 |
| Tracking Error | 1.0834 |
| Downside Risk | 16.3751 |
| Std. Deviation (Annualised) | 13.1211 |
| Sector Funds | 1M | 3M | 6M | 9M | 1Y | 3Y | 5Y | 10Y | ALL | Fund Size (Cr) | Exp. Ratio | Sharpe | Risk |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HDFC Pharma and Healthcare Fund - Regular Plan - Growth | -8.18% | -2.85% | 13.49% | 19.65% | 16.65% | 26.3% | N/A | N/A | 26.16% | 3,501.37 | 2.11 | 0.45 | Very High |
| SBI Healthcare Opportunities Fund - Regular Plan - IDCW | -7.91% | -3.95% | 12% | 16.9% | 9.98% | 20.31% | 16% | 12.88% | 16.36% | 5,870.00 | 1.99 | 0.33 | Very High |
| UTI Healthcare Fund - Regular Plan - IDCW | -8.04% | -4.49% | 10.8% | 14.7% | 7.94% | 19.65% | 13.41% | 12.86% | 14.71% | 1,429.84 | 2.22 | 0.32 | Very High |
| Mirae Asset Healthcare Fund - Regular Plan - Growth | -6.65% | -2.37% | 10.95% | 15.8% | 10.86% | 19.1% | 13.11% | N/A | 19.31% | 3,494.44 | 2.04 | 0.30 | Very High |
| ICICI Prudential Healthcare Fund - Growth | -5.27% | -5.77% | 5.31% | 6.11% | 1.04% | 18.9% | 14.21% | N/A | 18.53% | 6,861.20 | 2.08 | 0.30 | Very High |
| LIC MF Healthcare Fund - Regular Plan - Growth | -8.31% | -3.16% | 10.44% | 10.22% | 4.45% | 18.2% | 9.97% | N/A | 16.14% | 99.36 | 2.67 | 0.28 | Very High |
| DSP Healthcare Fund - Regular Plan - Growth | -5.87% | -2.13% | 13.11% | 11.93% | 9.74% | 17.47% | 13.29% | N/A | 20.34% | 3,750.04 | 2.05 | 0.29 | Very High |
| Aditya Birla Sun Life Pharma & Healthcare Fund - Regular Plan - Growth | -7.92% | -5.04% | 8.82% | 11.15% | 7.84% | 16.89% | 11.54% | N/A | 18.16% | 1,077.52 | 2.29 | 0.27 | Very High |
| Quant Healthcare Fund - Regular Plan - Growth | -7.41% | -1.49% | 10.61% | 18.21% | 9.71% | 16.57% | N/A | N/A | 17.69% | 424.53 | 3.13 | 0.23 | Very High |
| Nippon India Pharma Fund - Growth Current | -7.15% | -5.32% | 5.24% | 6.88% | 3.38% | 14.88% | 11.64% | 13.79% | 19.42% | 9,166.40 | 1.84 | 0.24 | Very High |
| Name | Sector | Instrument | Assets % |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 11.71% |
| Divi's Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 7.10% |
| Lupin Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 6.17% |
| Cipla Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 6.01% |
| Dr. Reddy's Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 5.45% |
| Apollo Hospitals Enterprise Ltd. | Healthcare Services | Domestic Equities | 4.89% |
| Mankind Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 4.38% |
| Sai Life Sciences Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 3.92% |
| Ajanta Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 3.61% |
| Glaxosmithkline Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 3.11% |
| Ipca Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.87% |
| Triparty Repo | Cash & Cash Equivalents and Net Assets | 2.81% | |
| Max Healthcare Institute Ltd. | Healthcare Services | Domestic Equities | 2.70% |
| Vijaya Diagnostic Centre Ltd. | Healthcare Services | Domestic Equities | 2.62% |
| Medplus Health Services Ltd. | Retailing | Domestic Equities | 2.53% |
| Gland Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.53% |
| Abbott India Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.32% |
| Piramal Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.24% |
| Thyrocare Technologies Ltd. | Healthcare Services | Domestic Equities | 2.24% |
| Dr. Lal Pathlabs Ltd. | Healthcare Services | Domestic Equities | 2.17% |
| Alkem Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.82% |
| Aurobindo Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.65% |
| Narayana Hrudayalaya Ltd. | Healthcare Services | Domestic Equities | 1.61% |
| Suraksha Diagnostic Ltd. | Healthcare Services | Domestic Equities | 1.51% |
| Syngene International Ltd. | Healthcare Services | Domestic Equities | 1.40% |
| Emcure Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.36% |
| Pfizer Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.35% |
| Akums Drugs & Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.21% |
| Anthem Biosciences Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.19% |
| Fortis Healthcare Ltd. | Healthcare Services | Domestic Equities | 1.13% |
| Biocon Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.01% |
| Sanofi India Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.00% |
| Sanofi Consumer Healthcare India Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 0.89% |
| Molbio Diagnostics Ltd. | Healthcare Equipment & Supplies | Domestic Equities | 0.54% |
| Indoco Remedies Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 0.48% |
| Astrazeneca Pharma India Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 0.42% |
| Concord Biotech Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 0.17% |
| Cash Margin - CCIL | Cash & Cash Equivalents and Net Assets | 0.02% | |
| Net Current Assets | Cash & Cash Equivalents and Net Assets | -0.13% | |
| Total | 100.00% | ||
Sailesh has Over 10 years experience in Equity Securities research and analysis. he is in Reliance Capital Asset Management Limited as managing various Schemes of Reliance Mutual Fund From 2003 to till date
Get personalized portfolio management services designed to grow and protect your wealth.
ChatGPT
Claude
Perplexity
